Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) insider Oxana Beskrovnaya sold 2,339 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the completion of the transaction, the insider now directly owns 140,375 shares in the company, valued at $4,849,956.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Dyne Therapeutics Stock Performance
Shares of NASDAQ:DYN opened at $36.59 on Friday. The firm has a market capitalization of $3.20 billion, a P/E ratio of -9.22 and a beta of 1.07. The stock has a 50 day moving average price of $41.07 and a 200-day moving average price of $33.61. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.45.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -2.96 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Piper Sandler raised their price target on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Stifel Nicolaus boosted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. upped their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Finally, Guggenheim upped their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.40.
Get Our Latest Stock Report on DYN
About Dyne Therapeutics
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Articles
- Five stocks we like better than Dyne Therapeutics
- Investing in the High PE Growth Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 9/16 – 9/20
- Financial Services Stocks Investing
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.